-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Zylox-Tonbridge Medical Technology (HKG:2190) Adds CN¥798m to Market Cap in the Past 7 Days, Though Investors From a Year Ago Are Still Down 67%
Zylox-Tonbridge Medical Technology (HKG:2190) Adds CN¥798m to Market Cap in the Past 7 Days, Though Investors From a Year Ago Are Still Down 67%
Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) shareholders should be happy to see the share price up 25% in the last month. But that's small comfort given the dismal price performance over the last year. Specifically, the stock price slipped by 67% in that time. The share price recovery is not so impressive when you consider the fall. Arguably, the fall was overdone.
While the last year has been tough for Zylox-Tonbridge Medical Technology shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
Check out our latest analysis for Zylox-Tonbridge Medical Technology
Because Zylox-Tonbridge Medical Technology made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last twelve months, Zylox-Tonbridge Medical Technology increased its revenue by 167%. That's well above most other pre-profit companies. Meanwhile, the share price slid 67%. Typically a growth stock like this will be volatile, with some shareholders concerned about the red ink on the bottom line (that is, the losses). We'd definitely consider it a positive if the company is trending towards profitability. If you can see that happening, then perhaps consider adding this stock to your watchlist.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
SEHK:2190 Earnings and Revenue Growth August 17th 2022We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this free report showing consensus forecasts
A Different Perspective
We doubt Zylox-Tonbridge Medical Technology shareholders are happy with the loss of 67% over twelve months. That falls short of the market, which lost 17%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. Putting aside the last twelve months, it's good to see the share price has rebounded by 16%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Zylox-Tonbridge Medical Technology by clicking this link.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Zylox-Tonbridge 医疗技术有限公司 (HKG: 2190) 股东应该很高兴看到股价在上个月上涨了25%。但是,考虑到去年令人沮丧的价格表现,这还算不上令人安慰。具体而言,那段时间股价下跌了67%。考虑到下跌,股价的回升并不那么令人印象深刻。可以说,下跌太过分了。
尽管去年对Zylox-Tonbridge Medical Technology的股东来说是艰难的一年,但上周显示出希望的迹象。因此,让我们看一下长期基本面,看看它们是否是负回报的驱动力。
查看我们对 Zylox-Tonbridge 医疗技术的最新分析
由于Zylox-Tonbridge Medical Technology在过去十二个月中出现了亏损,我们认为市场可能更关注收入和收入增长,至少目前是如此。无利可图公司的股东通常期望强劲的收入增长。那是因为可以很容易地将快速的收入增长推断为预测利润,通常规模相当大。
在过去的十二个月中,Zylox-Tonbridge Medical Technology的收入增加了167%。这远高于大多数其他盈利性公司。同时,股价下跌了67%。通常,像这样的成长型股票会波动不定,一些股东担心底线上的红色墨水(即亏损)。如果该公司趋向盈利,我们肯定会认为这是积极的。如果你能看到这种情况,那么可以考虑将这只股票添加到你的关注名单中。
下图显示了收入和收入随时间推移的跟踪情况(如果您点击图片,可以看到更多细节)。
SEHK: 2190 收益与收入增长 2022 年 8 月 17 日我们喜欢内部人士在过去十二个月中一直在购买股票。即便如此,未来的收益对于当前股东能否赚钱要重要得多。所以我们建议你看看这个 免费的 显示共识预测的报告
不同的视角
我们怀疑Zylox-Tonbridge Medical Technology的股东对十二个月内亏损67%感到满意。这低于市场,后者下跌了17%。毫无疑问,这令人失望,但在走强的市场中,该股的表现很可能会更好。撇开过去十二个月,很高兴看到股价在过去九十天内反弹了16%。这可能只是反弹,因为抛售过于激进,但这是新趋势的开始。喜欢赚钱的投资者通常会查看内幕收购,例如支付的价格和买入的总金额。点击此链接,你可以了解Zylox-Tonbridge Medical Technology的内幕收购情况。
如果你想与管理层一起买入股票,那么你可能会喜欢这个 免费的 公司名单。(提示:内部人士一直在购买它们)。
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧